| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.068 | 0.1 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.055 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.057 | 0.3 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.039 | 0.4 |